title: Deferasirox in a refractory anemia after other treatment options: case report and literature review.
abstract: Deferasirox, represents an effective iron chelator drug in lower risk myelodysplastic syndromes. Reduction in oxidative stress is responsible of the hematologic improvement but further explanation may impact on its benefit. Biological and clinical studies are necessary to better define mechanisms of action, assess toxicities, and predicting factors of response.
authors.affiliation: Department of Clinical Pathology, Riuniti University Hospital, Immunohematology and Transfusion Medicine Foggia, Italy ; Department of Oncology and Haematology, Marche Nord Hospital, Haematology and Haematopoietic Stem Cell Transplant Center Pesaro, Italy.
authors.forename: Palma
authors.initials: P
authors.lastname: Manduzio
keywords: Acute myeloid leukemia; Deferasirox; hematological improvement; iron overload; myelodysplastic syndrome